Teladoc Health (NYSE:TDOC) Price Target Lowered to $5.50 at Leerink Partners

Teladoc Health (NYSE:TDOC) had its price target lowered by Leerink Partners from $8.50 to $5.50 in a research report report published on Thursday,Benzinga reports. Leerink Partners currently has a market perform rating on the health services provider’s stock.

A number of other equities analysts have also commented on TDOC. Bank of America raised shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Thursday. Evercore decreased their target price on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research report on Thursday, October 30th. TD Cowen lowered their target price on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday. Zacks Research cut Teladoc Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Finally, Barclays began coverage on Teladoc Health in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Teladoc Health has an average rating of “Hold” and a consensus target price of $7.80.

Teladoc Health Stock Performance

NYSE:TDOC opened at $5.35 on Thursday. The stock has a 50 day simple moving average of $6.03 and a 200 day simple moving average of $7.21. The stock has a market cap of $949.46 million, a P/E ratio of -4.69 and a beta of 2.12. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $10.02. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 0.71.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.09% and a negative net margin of 7.92%.The firm had revenue of $642.27 million for the quarter, compared to analyst estimates of $635.33 million. During the same period in the prior year, the firm posted ($0.28) EPS. The company’s revenue for the quarter was up .3% on a year-over-year basis. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Research analysts anticipate that Teladoc Health will post -1.16 earnings per share for the current year.

Insider Activity

In other Teladoc Health news, insider Carlos Nueno sold 3,897 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $29,188.53. Following the completion of the transaction, the insider directly owned 27,175 shares in the company, valued at $203,540.75. The trade was a 12.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Fernando M. Rodrigues sold 4,209 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total value of $31,483.32. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 33,288 shares of company stock valued at $251,684. 0.58% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Teacher Retirement System of Texas boosted its stake in shares of Teladoc Health by 5.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 26,592 shares of the health services provider’s stock valued at $232,000 after purchasing an additional 1,431 shares in the last quarter. Federated Hermes Inc. increased its position in Teladoc Health by 0.5% during the 3rd quarter. Federated Hermes Inc. now owns 307,700 shares of the health services provider’s stock worth $2,379,000 after purchasing an additional 1,450 shares in the last quarter. Creative Planning lifted its stake in Teladoc Health by 7.7% in the 3rd quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock valued at $159,000 after purchasing an additional 1,462 shares during the last quarter. Krane Funds Advisors LLC boosted its position in Teladoc Health by 13.4% in the third quarter. Krane Funds Advisors LLC now owns 12,431 shares of the health services provider’s stock valued at $106,000 after buying an additional 1,469 shares in the last quarter. Finally, State of Wyoming grew its stake in shares of Teladoc Health by 2.1% during the third quarter. State of Wyoming now owns 79,075 shares of the health services provider’s stock worth $611,000 after buying an additional 1,628 shares during the last quarter. Institutional investors own 76.82% of the company’s stock.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss: Teladoc reported revenue of $642.3M (above estimates) and GAAP loss per share of $0.14 (better than consensus), driven by international growth and strength in Integrated Care; investors view the improved bottom line as a near-term positive. Teladoc Tops Q4 Earnings Estimates on International Growth & Lower Costs
• Positive Sentiment: Selective analyst support: Some firms are staying constructive (Bank of America upgraded to Buy, Piper Sandler reaffirmed Overweight, Canaccord remains a Buy despite lowering its PT), which bolsters demand from buyers who focus on recovery potential. Demystifying Teladoc Health: Insights From 8 Analyst Reviews
• Neutral Sentiment: Midterm growth roadmap: Management projects FY2026 revenue of roughly $2.47B–$2.59B and emphasized investments in AI, insurance relationships and international expansion — initiatives that support longer-term upside but will take time to materialize. Teladoc projects $2.47B–$2.59B revenue in 2026
• Negative Sentiment: Cautious forward guidance: Q1 2026 revenue guidance ($598M–$620M) and EPS guidance (-$0.45 to -$0.35) came in below Wall Street expectations, and FY EPS guidance (-$1.10 to -$0.70) is wider/weaker than consensus — a key reason for mixed investor reactions despite the quarter’s beat. Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Analyst price-target cuts: Several firms trimmed price targets (BMO, TD Cowen, Stifel, Wells Fargo, Leerink) and moved to Market Perform/Hold ratings in response to the softer outlook, adding selling pressure for investors focused on nearer-term valuation and earnings visibility. Analyst price-target updates

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.